US Patent Issued to Novartis, The Trustees of the University of Pennsylvania on April 7 for "Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer" (Massachusetts Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,594,321, issued on April 7, was assigned to Novartis AG (Basel, Switzerland) and The Trustees of the University of Pennsylvania (Philadelphia).

"Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer" was invented by Barbara Brannetti (Cambridge, Mass.), Jennifer Brogdon (Sudbury, Mass.), Boris Engels (Arlington, Mass.), Brian Walter Granda (Salisbury, Mass.), Ming Lei (Acton, Mass.) and Jimin Zhang (Chestnut Hill, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compositions and methods for treating diseases associated with expression o...